Advirna

Advirna will present it’s siRNA drug discovery platform at ATGC24 conference.

Single dose of zilebesiran safely and effectively lowered blood pressure for six months Research Highlights: The phase 2 study found that a single injection of the experimental medication zilebesiran safely and effectively lowered blood pressure in adults with mild-to-moderate hypertension for up to six months. Based on these results,...

Advirna will be presenting a poster at the Nucleic Acids Therapies conference at Cold Spring Harbor Laboratory (March 22-25).

We published a paper in Molecular Therapy Nucleic Acids demonstrating a potential use of self-deliverable siRNA conjugates (sdRNAs) to prevent ocular scarring

USP10 Targeted Self-Deliverable siRNA to Prevent Scarring in the Cornea Ocular scarring after surgery, trauma, or infection leads to vision loss. The transparent cornea is an excellent model system to test anti-scarring th…